A counterintuitive discovery challenges assumptions about how brain immune cells protect against neurodegeneration. While enhanced receptor function typically suggests improved cellular activity, this finding reveals that sometimes more activation leads to worse outcomes for cognitive health.
Researchers identified that the TREM2-T96K genetic variant, despite increasing the receptor's ligand-binding capacity, elevates Alzheimer's disease risk by disrupting crucial microglial behaviors. In female mouse models, this mutation prevented immune cells from clustering around amyloid plaques and reduced their ability to engulf toxic protein aggregates. Single-cell sequencing revealed the variant blocks microglia from transitioning into their disease-fighting phenotype, leaving them trapped in a less effective homeostatic state. The mutation also suppressed critical inflammatory pathways including IL-6/JAK/STAT3 signaling and complement activation.
This paradox illuminates the delicate balance required for effective brain immunity. Microglia must calibrate their response precisely—neither underreacting to threats nor becoming hyperactivated. The T96K variant appears to dysregulate this balance, creating cellular confusion that undermines protective functions despite enhanced receptor sensitivity. The sex-specific effects observed in females align with known differences in microglial behavior and Alzheimer's risk patterns between men and women. These findings suggest that therapeutic approaches targeting TREM2 must consider both the direction and magnitude of receptor modulation. Rather than simply amplifying or suppressing activity, successful interventions may need to restore optimal signaling dynamics, particularly in female patients who show heightened vulnerability to this particular genetic variant.